Target intelligence / Profile preview

Coxiella burnetii (C. burnetii)

Target
C. burnetii
Molecular classification
Other (Bacterium, intracellular pathogen, Gram-negative bacterium)
01

Overview

Coxiella burnetii is a small, Gram-negative, pleomorphic, obligately intracellular bacterium of the class Gammaproteobacteria, order Legionellales. It is the etiological agent of Q fever, causing both acute and chronic infections in humans and animals. The bacterium primarily infects monocytes/macrophages and replicates within a specialized vacuole resembling a phagolysosome. It has a biphasic life cycle with environmentally resistant small cell variants and metabolically active large cell variants. Disease transmission typically occurs via aerosolized particles from infected animals or animal products. Because of its very low infectious dose, environmental stability, and potential for airborne spread, C. burnetii is considered a possible agent of bioterrorism. Treatment relies on prolonged antibiotic regimens, often with doxycycline and hydroxychloroquine, and preventive vaccination is available but limited by strong reactogenicity in previously sensitized individuals.

Other names
Nine Mile agentQ fever agentC. burnetii
02

Mechanism of action

Antibiotics: Inhibit bacterial protein synthesis or DNA replication (e.g., doxycycline inhibits the 30S ribosomal subunit, rifampin inhibits RNA polymerase). Host-directed drugs: Alter host cell signaling or immune responses to inhibit bacterial replication (not direct action on the bacterium itself).

03

Biological functions

Infectionevasion of host immune responseintracellular survivalreplication in macrophagesmanipulation of host cell pathways
04

Disease associations

Infection (Q fever, endocarditis, chronic infections)
05

Safety considerations

Chronic infection risk (especially endocarditis in immunocompromised or cardiac patients)Antibiotic resistance (emerging strains demonstrate resistance to traditional antimicrobials)Reactogenicity to whole cell vaccines in previously exposed individuals (hypersensitivity reactions)Persistence of infection requiring prolonged combination antibiotic therapy
06

Interacting drugs

Doxycycline

9 more in the full profile.

07

Biomarkers

Serological detection of phase I/II antibodies (IgG/IgM against phase I and II lipopolysaccharide)PCR detection of C. burnetii DNAIFNγ release assays for cellular immunity

Beyond the preview

Go deeper on Coxiella burnetii (C. burnetii).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coxiella burnetii (C. burnetii).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call